BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9512763)

  • 1. Adverse effects of cytotoxics-platinum agents.
    Selvaratnam G; Philips RH; Mohamed AK; Radzi A
    Adverse Drug React Toxicol Rev; 1997 Aug; 16(3):171-97. PubMed ID: 9512763
    [No Abstract]   [Full Text] [Related]  

  • 2. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
    Hayek M; Srinivasan A
    Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
    [No Abstract]   [Full Text] [Related]  

  • 3. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    Ali BH; Al Moundhri MS
    Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention and treatment of the side effects of cancer chemotherapy].
    Iki S; Urabe A
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1635-40. PubMed ID: 11057312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [About side effects of platinum drugs].
    Waszkiewicz K
    Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
    Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
    Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemistry of the peripheral and central auditory system after ototoxic drug exposure: implications for tinnitus.
    Rybak LP
    Int Tinnitus J; 2005; 11(1):23-30. PubMed ID: 16419684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amifostin in protection of kidney from cisplatinum injury].
    Cui H; Zhang S; Li P; Guan Z; Sun X; Shen K; Wu M; Hu X; Liu S; Di L; Zhang S
    Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):48-50. PubMed ID: 11977638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
    Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
    Cronin S; Uberti JP; Ayash LJ; Raith C; Ratanatharathorn V
    Bone Marrow Transplant; 2000 Dec; 26(11):1247-9. PubMed ID: 11149742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
    Goren MP
    Med Pediatr Oncol; 2003 Sep; 41(3):186-9. PubMed ID: 12868117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
    Korst AE; van der Sterre ML; Eeltink CM; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
    Clin Cancer Res; 1997 May; 3(5):697-703. PubMed ID: 9815738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future directions in gynecologic cancer.
    Alberts DS
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):125-8. PubMed ID: 10348271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
    Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
    Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S; Chewaskulyong B
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity from chemotherapy: prevention and management.
    Vogelzang NJ
    Oncology (Williston Park); 1991 Oct; 5(10):97-102, 105; disc. 105, 109-11. PubMed ID: 1838278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity.
    Bianchi R; Brines M; Lauria G; Savino C; Gilardini A; Nicolini G; Rodriguez-Menendez V; Oggioni N; Canta A; Penza P; Lombardi R; Minoia C; Ronchi A; Cerami A; Ghezzi P; Cavaletti G
    Clin Cancer Res; 2006 Apr; 12(8):2607-12. PubMed ID: 16638873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.